Tenecteplase

BLOOD AND BLOOD FORMING ORGANS

Key facts

Tenecteplase is a drug catalogued in DrugCentral. It was first approved by the FDA in 2000. DrugCentral lists 1 molecular target, including PLG. Recorded indications include Acute myocardial infarction and Ankylosing spondylitis.

• Molecular targets: PLG (1 listed in DrugCentral).
• Indications: Acute myocardial infarction and Ankylosing spondylitis.
• ATC code: B01AD11 (Enzymes).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Acute myocardial infarction
• Ankylosing spondylitis

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Plasminogen	PLG	activator	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2001-02-23	EMA	—	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
2000-06-02	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
B01AD11	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Enzymes

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
No adverse event	1016.7
Cerebral haemorrhage	576.5
Off label use	495.1
Haemorrhage intracranial	461.6
Angioedema	402.4
Haemorrhagic transformation stroke	322.2
Haemorrhage	161.2
Subarachnoid haemorrhage	151.5
Neurological decompensation	116.2
Cardiogenic shock	88.7
Cerebral infarction	80.5
Wrong product administered	78.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 191588-94-0
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tenecteplase used for?

DrugCentral lists the following indications for Tenecteplase: Acute myocardial infarction and Ankylosing spondylitis.

How does Tenecteplase work?

Its molecular targets in DrugCentral include PLG (activator).

When was Tenecteplase first approved?

Tenecteplase was first approved by the FDA in 2000.

Sources

• DrugCentral drug card 5066 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2108791 — compound record and bioactivity
• DrugBank DB00031 — drug record
• FDA UNII WGD229O42W — substance identity
• DailyMed: FDA labels for Tenecteplase — current prescribing information (label search)
• UniProt P00747 (PLG) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.